Product Images Pazopanib

This text provides information about a clinical trial comparing pazopanib to a placebo in terms of progression-free survival. The results show that patients on pazopanib had a median progression-free survival of 4.6 months compared to 1.6 months for those on placebo. The hazard ratio was found to be 0.35 with a 95% confidence interval of 0.26 to 0.48, indicating a significant difference between the two groups (P value < 0.001).*

Proportion Progression-Free: This data shows the comparison between Pazopanib (administered to 290 subjects) and Placebo (administered to 145 subjects) in terms of median progression-free survival. The results indicate that the median progression-free survival was 9.2 months for Pazopanib and 4.2 months for Placebo. The Hazard Ratio was calculated as 0.46 with a 95% confidence interval of (0.34, 0.62) and a statistically significant p-value of less than 0.001.*

Each tablet of NoC 82263-022-10 contains 200 mg of pazopanib free base equivalent to 216.7 mg of pazopanib hydrochloride. The prescribed dosage should be followed as per the accompanying information. Store the tablets at a temperature between 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). Ensure the printed safety seal under the cap is intact before use. Pharmacists should dispense the medication guide with each order of 120 tablets.*